Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2012

01.09.2012 | Brief Communication

Vitamin D Receptor Gene Variants and Esophageal Adenocarcinoma Risk: A Population-Based Case–Control Study

verfasst von: C. K. Chang, H. G. Mulholland, M. M. Cantwell, L. A. Anderson, B. T. Johnston, A. J. McKnight, P. D. Thompson, R. G. P. Watson, L. J. Murray, on behalf of the FINBAR study group

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Polymorphisms in the vitamin D receptor (VDR) gene may be of etiological importance in determining cancer risk. The aim of this study was to assess the association between common VDR gene polymorphisms and esophageal adenocarcinoma (EAC) risk in an all-Ireland population-based case–control study.

Methods

EAC cases and frequency-matched controls by age and gender recruited between March 2002 and December 2004 throughout Ireland were included. Participants were interviewed, and a blood sample collected for DNA extraction. Twenty-seven single nucleotide polymorphisms in the VDR gene were genotyped using Sequenom or TaqMan assays while the poly(A) microsatellite was genotyped by fluorescent fragment analysis. Unconditional logistic regression was applied to assess the association between VDR polymorphisms and EAC risk.

Results

A total of 224 cases of EAC and 256 controls were involved in analyses. After adjustment for potential confounders, TT homozygotes at rs2238139 and rs2107301 had significantly reduced risks of EAC compared with CC homozygotes. In contrast, SS alleles of the poly(A) microsatellite had significantly elevated risks of EAC compared with SL/LL alleles. However, following permutation analyses to adjust for multiple comparisons, no significant associations were observed between any VDR gene polymorphism and EAC risk.

Conclusions

VDR gene polymorphisms were not significantly associated with EAC development in this Irish population. Confirmation is required from larger studies.
Literatur
1.
Zurück zum Zitat Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Renal Physiol. 2005;289:F8–28.CrossRef Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Renal Physiol. 2005;289:F8–28.CrossRef
2.
Zurück zum Zitat Ebert R, Schutze N, Adamski J, Jakob F. Vitamin D signalling is modulated on multiple levels in health and disease. Mol Cell Endocrinol. 2006;248:149–59.PubMedCrossRef Ebert R, Schutze N, Adamski J, Jakob F. Vitamin D signalling is modulated on multiple levels in health and disease. Mol Cell Endocrinol. 2006;248:149–59.PubMedCrossRef
3.
Zurück zum Zitat Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev. 2003;24:13–26.PubMed Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev. 2003;24:13–26.PubMed
4.
Zurück zum Zitat Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164–9.PubMedCrossRef Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164–9.PubMedCrossRef
5.
Zurück zum Zitat Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1 and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1990–9.PubMedCrossRef Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1 and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1990–9.PubMedCrossRef
6.
Zurück zum Zitat Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef
7.
Zurück zum Zitat De Gottardi A, Dumonceau JM, Bruttin F, et al. Expression of the bile acid receptor FXR in Barrett’s esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer. 2006;5:48–58.PubMedCrossRef De Gottardi A, Dumonceau JM, Bruttin F, et al. Expression of the bile acid receptor FXR in Barrett’s esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer. 2006;5:48–58.PubMedCrossRef
8.
Zurück zum Zitat Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–82.PubMedCrossRef Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–82.PubMedCrossRef
9.
Zurück zum Zitat Mulholland HG, Cantwell MM, Anderson LA, et al. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Causes Control. 2009;20:279–88.PubMedCrossRef Mulholland HG, Cantwell MM, Anderson LA, et al. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Causes Control. 2009;20:279–88.PubMedCrossRef
10.
Zurück zum Zitat Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–94.PubMed Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–94.PubMed
11.
Zurück zum Zitat Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80 Suppl 1:95–103.PubMed Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80 Suppl 1:95–103.PubMed
12.
Zurück zum Zitat Nejentsev S, Godfrey L, Snook H, et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet. 2004;13:1633–9.PubMedCrossRef Nejentsev S, Godfrey L, Snook H, et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet. 2004;13:1633–9.PubMedCrossRef
13.
Zurück zum Zitat Slatter ML, Yakumo K, Hoffman M. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control. 2001;12:359–64.PubMedCrossRef Slatter ML, Yakumo K, Hoffman M. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control. 2001;12:359–64.PubMedCrossRef
14.
Zurück zum Zitat Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet. 2005;76:887–93.PubMedCrossRef Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet. 2005;76:887–93.PubMedCrossRef
15.
Zurück zum Zitat Whitfield GK, Remus LS, Jurutka PW, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–59.PubMedCrossRef Whitfield GK, Remus LS, Jurutka PW, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–59.PubMedCrossRef
16.
Zurück zum Zitat Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.PubMedCrossRef Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.PubMedCrossRef
17.
Zurück zum Zitat Li D, Diao Y, Li H, et al. Association of the polymorphisms of MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous dysplasia and carcinoma. Arch Med Res. 2008;39:594–600.PubMedCrossRef Li D, Diao Y, Li H, et al. Association of the polymorphisms of MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous dysplasia and carcinoma. Arch Med Res. 2008;39:594–600.PubMedCrossRef
18.
Zurück zum Zitat Mulholland HG, Murray LJ, Anderson LA, et al. Vitamin D, calcium and dairy intake and risk of oesophageal adenocarcinoma and its pre-cursor conditions. Br J Nutr. 2011;011(9):1–10. Mulholland HG, Murray LJ, Anderson LA, et al. Vitamin D, calcium and dairy intake and risk of oesophageal adenocarcinoma and its pre-cursor conditions. Br J Nutr. 2011;011(9):1–10.
19.
Zurück zum Zitat Köstner K, Denzer N, Müller CS, et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMed Köstner K, Denzer N, Müller CS, et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMed
Metadaten
Titel
Vitamin D Receptor Gene Variants and Esophageal Adenocarcinoma Risk: A Population-Based Case–Control Study
verfasst von
C. K. Chang
H. G. Mulholland
M. M. Cantwell
L. A. Anderson
B. T. Johnston
A. J. McKnight
P. D. Thompson
R. G. P. Watson
L. J. Murray
on behalf of the FINBAR study group
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2012
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-011-9322-9

Weitere Artikel der Ausgabe 3/2012

Journal of Gastrointestinal Cancer 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.